NBIXNeurocrine Biosciences, Inc.
$165.00
$4.62
(2.86%)
Closed $166.06
$1.06
(0.64%)
After Hours
EarningsJul 29
Mkt Cap$16.23B
Vol1.36M
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
Zacks
Best Momentum Stocks to Buy for June 24th
NBIX, ILPT and CASY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24th, 2026.
Zacks
New Strong Buy Stocks for June 24th
BY, NVGS, NBIX, TFII and BG have been added to the Zacks Rank #1 (Strong Buy) List on June 24th, 2026.
Zacks
Best Value Stocks to Buy for June 24th
NVGS, BY and NBIX made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 24th, 2026.
Zacks
Soleno Therapeutics Presents New VYKAT XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Soleno Therapeutics Presents New VYKAT XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics Presents New VYKAT XR (diazoxide choline) Data...
PR Newswire
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11Hydroxylase Deficiency at ENDO 2026
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11Hydroxylase Deficiency at ENDO 2026 Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY (crinecerfont) in Patients...
PR Newswire
Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improved Growth...
PR Newswire
Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating...
PR Newswire
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA (valbenazine) Capsules Across a Broad Range of Patients
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA (valbenazine) Capsules Across a Broad Range of Patients Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive...
PR Newswire
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities Neurocrine Biosciences Presents New Data Highlighting Functional and...
PR Newswire
<
1
2
...
>